Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Ellen L. Goode(Mayo Clinic in Arizona), Naveena Singh(University of British Columbia), Jennifer Alsop(Manchester Academic Health Science Centre), Janusz Menkiszak(Pomeranian Medical University), Brooke L. Fridley(Children's Mercy Hospital), Jesús García-Donás(Universidad San Pablo CEU), Florin‐Andrei Taran(University Children's Hospital Tübingen), Zachary C. Fogarty(Mayo Clinic in Florida), Allan Jensen(Danish Cancer Society), Daniel Guimarães Tiezzi(Mayo Clinic), Matthias Ruebner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Bryan M. McCauley(University of Minnesota), Andy Ryan(Breast Cancer Now), Robert A. Vierkant(Mayo Clinic), Jan Lubiński(Tumour Institute of Tuscany), Aliecia L. Bouligny(Spelman College), Jill Nation(University of Calgary), Anita Chudecka-Głaz(Pomeranian Medical University), Brenda Y. Hernandez(Cancer Center of Hawaii), Gregg Nelson(Brigham and Women's Hospital), Andreas D. Hartkopf(University of Tübingen), Ana Osório(Spanish National Cancer Research Centre), Martin Widschwendter(Universität Innsbruck), Matthias W. Beckmann(Universitätsklinikum Erlangen), Arndt Hartmann(Universitätsklinikum Erlangen), Catherine J. Kennedy(The University of Sydney), Aleksandra Gentry‐Maharaj(UCL Australia), Kimberly R. Kalli(Mayo Clinic), Maria P. Intermaggio(The University of Melbourne), Audrey Jung(German Cancer Research Center), Bo Gao(Sun Yat-sen University), Francesmary Modugno(University of Pittsburgh), Aleksandra Tołoczko(International Hereditary Cancer Center), Esther Herpel(Memorial Sloan Kettering Cancer Center), Anthony M. Magliocco(Cancer Prevention Institute of California), Chloe Karpinskyj(Breast Cancer Now), Jenny Lester, Alexander Hein, Jurandyr Moreira de Andrade(Universidade de São Paulo), Chen Wang(Xiamen University), Wenqian Chen(Imperial College London), José Palacios(Universidad de Alcalá), Joseph H. Rothstein(University of Washington Medical Center), David L. Wachter, Christiani Bisinoto de Sousa(Universidade de São Paulo), Joseph L. Kelley(Magee-Womens Hospital), Matthew S. Block(Mayo Clinic in Arizona), Jillian A. Hung(Millennium Institute), Mercedes Jimenez‐Liñan(University of Kansas)
Cited by 409
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
Genomic and Functional Approaches to Understanding Cancer Aneuploidy
|Cancer Cell|2018|1.2k